AstraZeneca's antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be authorised for prevention of infection by the US FDA.
As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild or moderate COVID-19 from devel
AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healt
AstraZeneca's AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first time this has been demonstrated by a long-acting antibody-based drug.
The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and prevent coronavirus infec
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat